HIV Infection Clinical Trial
— REFRESHOfficial title:
A Phase I/II Randomized, Double-Blind, Placebo Controlled Study of Repeated Low-Dose Fecal Microbiota Restoration in HIV-Infected Subjects. The REFRESH Study
Altered interplay between gut mucosa and dysbiotic bacteria during HIV infection seems to contribute to chronic immune dysfunction. Manipulation of the intestinal microbiota with nutritional interventions exert limited immunologic effects, but a deep understanding of how these interventions could ameliorate gut dysbiosis and influence health among HIV-infected individuals remain unexplored. In this Phase I clinical trial, 30 HIV-infected subjects on effective ART with evidence of persistent immune dysfunction, indicated by a CD4/CD8 ratio<1 will be included and randomized to either repeated low-dose oral fecal microbiota transplantation or placebo during 8 weeks. The primary outcome will be safety. Secondary outcomes will include changes in CD4+ T cell counts, CD8+ T cell counts, CD4/CD8 ratio, inflammatory markers, T cell activation and markers of enterocyte barrier function through week 48. Engraftment on host microbiota will be examined using Illumina sequencing of the V3-V4 16S RNA, and changes in bacterial metabolism and in the plasma metabolite fingerprint will be studied by combination of untargeted mass spectrometry and two different and complementary separation techniques in bacterial and plasma samples.
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - On stable antiretroviral therapy with plasma HIV RNA <20 copies/mL during at least 48 weeks. - CD4/CD8 ratio <1 Exclusion Criteria: - Pregnancy - Gastrointestinal diseases, including cirrhosis - Active infections, including HCV - EBV and/or CMV negative patients (donors are not screened for EBV/CMV). - Planned used of chemotherapy or antibiotics - Allergy to sodium chloride or glycerol (the former components are capsule ingredients Generally Recognized As Safe (GRAS) - Current or planned use of antimicrobial agents (including prophylactic treatments against P. jiroveci) other than ART. - Neutropenia <500 cells/uL or CD4 counts <350 cells/uL - Patients unable to give informed consent - Patients unable to comply with the protocol requirements - Predicted death within time period of follow-up - Any other condition for which the treating physician thinks the treatment may pose a health risk - Dysphagia: oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, ALS) - History of aspiration - History of gastroparesis |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Ramón y Cajal | Madrid |
Lead Sponsor | Collaborator |
---|---|
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | From baseline through week 48 | ||
Secondary | Changes in CD4+ T cell counts | From baseline through week 48 | ||
Secondary | Changes in CD8+ T cell counts | Inflammation: interleukin (IL)-6, high sensitivity C reactive protein (hs-CRP), interferon gamma-induced protein (IP)-10. Monocyte/macrophage activation: sCD14, SCD163, Gut epithelial integrity: zonulin-1, intestinal fatty acid binding protein (IFABP). Bacterial translocation: lipoteichoic acid (LTA) Indolamine deoxygenase-1 induction: kynurenine/tryptophan ratio Coagulation: D-dimers |
From baseline through week 48 | |
Secondary | Changes in CD4/CD8 ratio | Inflammation: interleukin (IL)-6, high sensitivity C reactive protein (hs-CRP), interferon gamma-induced protein (IP)-10. Monocyte/macrophage activation: sCD14, SCD163, Gut epithelial integrity: zonulin-1, intestinal fatty acid binding protein (IFABP). Bacterial translocation: lipoteichoic acid (LTA) Indolamine deoxygenase-1 induction: kynurenine/tryptophan ratio Coagulation: D-dimers |
From baseline through week 48 | |
Secondary | Changes in microbiota alpha diversity metrics | From baseline through week 48 | ||
Secondary | Changes in microbiota Unifrac distances | From baseline through week 48 | ||
Secondary | Changes in microbiota Canberra distances | From baseline through week 48 | ||
Secondary | Changes in plasma Interleukin-6 levels | From baseline through week 48 | ||
Secondary | Changes in plasma hs-CRP levels | From baseline through week 48 | ||
Secondary | Changes in plasma lipoteichoic acid levels | From baseline through week 48 | ||
Secondary | Changes in plasma LBP levels | From baseline through week 48 | ||
Secondary | Changes in plasma kynurenine/tryptophan ratio | From baseline through week 48 | ||
Secondary | Percentage of HLA-DR+/CD38+ T cells in blood | From baseline through week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01805427 -
Antiretroviral Therapy and Extreme Weight
|
N/A |